JPS62205010A - Hair tonic - Google Patents
Hair tonicInfo
- Publication number
- JPS62205010A JPS62205010A JP4677186A JP4677186A JPS62205010A JP S62205010 A JPS62205010 A JP S62205010A JP 4677186 A JP4677186 A JP 4677186A JP 4677186 A JP4677186 A JP 4677186A JP S62205010 A JPS62205010 A JP S62205010A
- Authority
- JP
- Japan
- Prior art keywords
- formulas
- tables
- hair
- chemical formulas
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 54
- 230000001256 tonic effect Effects 0.000 title abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000194 kebuzone Drugs 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- FFZZOHKZRFIQBW-BIHUAPLPSA-N (8r,9s,10r,13s,14s,17s)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 FFZZOHKZRFIQBW-BIHUAPLPSA-N 0.000 claims 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 abstract description 7
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 33
- 230000003779 hair growth Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- -1 β-ethoxy Chemical class 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- XWFWMYFLNHTEBF-YFWFAHHUSA-N methyl (8s,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-17-carboxylate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)OC)[C@@]1(C)CC2 XWFWMYFLNHTEBF-YFWFAHHUSA-N 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 3
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- 229930007845 β-thujaplicin Natural products 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JSCWUBYUVGMWBE-UHFFFAOYSA-N (7-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-yl)methanol Chemical compound C1=C(Cl)C=C2S(=O)(=O)NC(CO)=NC2=C1 JSCWUBYUVGMWBE-UHFFFAOYSA-N 0.000 description 1
- MSEZLHAVPJYYIQ-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 MSEZLHAVPJYYIQ-VMXHOPILSA-N 0.000 description 1
- IATKKATWPOVYCC-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 IATKKATWPOVYCC-VMXHOPILSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- YZGMEGPSJBJPHS-UHFFFAOYSA-N 2-chloro-3-methyl-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)N(Cl)C(C)=NC2=C1 YZGMEGPSJBJPHS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- 125000002173 5α-dihydrotestosterone group Chemical group 0.000 description 1
- LWHZIAMUYGUQSY-UHFFFAOYSA-N 7-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-3-carboxylic acid Chemical compound C(=O)(O)C=1NS(C2=C(N=1)C=CC(=C2)Cl)(=O)=O LWHZIAMUYGUQSY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101100162792 Arabidopsis thaliana AOX1A gene Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 229960002326 bithionol Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は優れた養毛効果を持つ養毛料に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a hair nourishing agent having excellent hair nourishing effects.
男性型の禿頭や脂漏などの生理学上の徴候は、男性ホル
モンの過剰蓄積に基づく男性ホルモン刺激の増大による
と言われているが、最近、毛根、皮脂線などの器官にお
けるこの男性ホルモン活性の本体は、これら標的器官に
おいてテストステロン(男性ホルモン)がテストステロ
ン−5α−レダクターゼという名の酵素(以下、レダク
ターゼと略す。)によって還元された5α−ジヒドロテ
ストステロン(以下、5α−DHTと略す。)であるこ
とが周知となってきている。即ち、来光や副腎で作られ
たテストステロンは血流に乗って皮脂線に行き、皮脂線
細胞の中にあるレダクターゼによって、より強力な男性
ホルモンである5α−DHTに変換される。この5α−
DHTは細胞内の受容体と結合し、核に働いて皮脂線細
胞の増殖を促す一方、それ自体が皮脂線細胞外に出て血
流に乗り、毛母の細胞に働き毛球部の毛母細胞の分裂を
抑制し、毛の成長を妨げ、抜毛、脱毛を促進するものと
されてる。Physiological symptoms such as male-pattern baldness and seborrhea are said to be due to increased stimulation of androgen due to excessive accumulation of androgen, but recently it has been reported that this androgenic activity in organs such as hair roots and sebaceous glands has been increased. The main body is 5α-dihydrotestosterone (hereinafter abbreviated as 5α-DHT), which is produced by reducing testosterone (male hormone) in these target organs by an enzyme called testosterone-5α-reductase (hereinafter abbreviated as reductase). This is becoming well known. That is, testosterone produced in the rays and adrenal glands travels through the bloodstream to the sebaceous glands, where it is converted into 5α-DHT, a more powerful male hormone, by reductase in the sebaceous gland cells. This 5α-
DHT binds to intracellular receptors and acts on the nucleus to promote the proliferation of sebaceous cells, while DHT itself exits the sebaceous cells and enters the bloodstream, acting on hair matrix cells and stimulating the growth of hair in the hair bulb. It is said to suppress the division of mother cells, impede hair growth, and promote hair pulling and hair loss.
従って、男性型の禿頭や脱毛などの徴候は、レダクター
ゼの活性を阻害すること、および5α−D HTと受容
体タンパクとの結合を阻害することにより低減または防
止することができると考えられ、この観点に基づいてこ
れまでにクロルマジノンアセテート、オレイン酸、リノ
ール酸などの物質が見い出されている。しかしながら、
これらの物質はレダクターゼ活性の阻害率は大きくても
好ましぐない副作用があったり、5α−D HTと豊容
体タンパクとの結合阻害率が非常に低かったりして、実
質上の養毛効果に劣るという欠点があった。Therefore, it is thought that symptoms such as male pattern baldness and hair loss can be reduced or prevented by inhibiting reductase activity and the binding of 5α-D HT to receptor proteins. Based on this viewpoint, substances such as chlormadinone acetate, oleic acid, and linoleic acid have been discovered so far. however,
Although these substances have a high inhibition rate of reductase activity, they may have unfavorable side effects, or have a very low rate of inhibition of binding between 5α-D HT and fertility proteins, so they have no substantial hair growth effect. It had the disadvantage of being inferior.
本発明者らは、上記事項に鑑み、ホルモン作用などの好
ましくない副作用を持たず、安全で、かつレダクターゼ
活性の阻害作用および5α−D HTと受容体タンパク
との結合阻害作用を併せ持つ物質を探究し、これを配合
することにより養毛効果の優れた養毛料を得るべく鋭意
研究を重ねた結果、特定のステロイド誘導体を配合する
ことによって上記目的を達っし得ることを見いだし、先
に特許出願をおこなった(特開昭60−54310 、
特開昭60−81121 、特開昭59−184114
、特開昭60−81122 、特開昭60−13650
5、特開昭60−67411、特願昭60−27394
8)。In view of the above, the present inventors sought to find a substance that is safe, does not have undesirable side effects such as hormonal effects, and has both an inhibitory effect on reductase activity and an inhibitory effect on the binding between 5α-D HT and receptor protein. As a result of extensive research in order to obtain a hair nourishing agent with excellent hair nourishing effects by blending this, we discovered that the above purpose could be achieved by blending a specific steroid derivative, and we filed a patent application earlier. (Japanese Patent Application Laid-Open No. 60-54310,
JP-A-60-81121, JP-A-59-184114
, JP-A-60-81122, JP-A-60-13650
5. Japanese Patent Publication No. 60-67411, Patent Application No. 60-27394
8).
さらに、本発明者らが研究した結果、特開昭56−65
811において毛髪育成促進剤として開示されている〔
ベンゾ−1,2,4−チアジアジンツー1−ジオキサイ
ド誘導体を上記特定のステロイド誘導体と組み合わせて
配合すると、その効果が相乗的に増大することを見い出
し本発明を完成するに至った。Furthermore, as a result of research by the present inventors,
811 as a hair growth promoter [
The present inventors have discovered that when a benzo-1,2,4-thiadiazine-1-dioxide derivative is blended with the above-mentioned specific steroid derivative, the effects thereof are synergistically increased, leading to the completion of the present invention.
(以下余白)
すなわち、本発明は下記(a)の群の中から選ばれる少
なくとも一種と、下記(b)の群の中から選ばれる少な
くとも一種とを含をすることを特徴とする養毛料である
。(The following is a blank space) That is, the present invention is a hair nourishing product characterized by containing at least one selected from the group (a) below and at least one selected from the group (b) below. be.
(a)■下記一般式(1)で示される4−エストレン−
3−オン−1フβ−エトキシ誘導体もしくは4−アンド
ロステン−3−オン−17β−エトキシ誘導体。(a)■ 4-estrene- represented by the following general formula (1)
3-one-1 β-ethoxy derivative or 4-androsten-3-one-17β-ethoxy derivative.
(以下余白)
(式中R1はH,−CI+3を表わし、R2は−CH2
0H1−CH20COX (但しXは炭素数1〜5のア
ルキル基、フェニル基を表わす。)、−CH2Y(但し
YはF、 CI、 Br、 Iを表わす。)、−CI2
CN、−COOX(但しXは上記と同一)、■下記一般
式(2)で示される4−アンドロステン−3,17−シ
オンー17−サイクリツクニチレンケクール誘導体。(Left below) (In the formula, R1 represents H, -CI+3, and R2 represents -CH2
0H1-CH20COX (wherein X represents an alkyl group having 1 to 5 carbon atoms or a phenyl group), -CH2Y (however, Y represents F, CI, Br, or I), -CI2
CN, -COOX (where X is the same as above), (2) A 4-androstene-3,17-sion-17-cyclic nitylenic derivative represented by the following general formula (2).
R,R2
(以下余白)
■4−アンドロステンー3−オンー17β−カルボン酸
アルキルエステル。R, R2 (blank below) ■4-Androsten-3-one-17β-carboxylic acid alkyl ester.
■4−ニストレンー3−オンー17β−カルボン酸およ
びそのアルキルエステル。(2) 4-Nistrene-3-one-17β-carboxylic acid and its alkyl ester.
■4−ニストレンー3.17−シオンー17−サイクリ
ックエチレンケタノール。■4-Nistrene-3.17-Sion-17-cyclic ethylene ketanol.
(b)下記一般式(3)で示される〔ベンゾ−1,2゜
4−チアジアジンツー1−ジオキサイド誘導体。(b) [benzo-1,2°4-thiadiazine-1-dioxide derivative represented by the following general formula (3).
(以下余白)
(式ヴR1はCI、−CF3、−502 NlI2を表
わし、R2はILCI、−502Nl12を表わしく但
しR1およびR2が両方同時にCIであることあるいは
両方同時に一5o2Ni12であることはない)、Rり
はI(。(Left below) (Formula V R1 represents CI, -CF3, -502NlI2, and R2 represents ILCI, -502Nl12. However, R1 and R2 cannot both be CI at the same time, or both cannot be -5o2Ni12 at the same time. ), Riri is I (.
炭素数1〜3 のアルキル基、−C11,2CI、−C
IICI2 、−CCI コ 、 −COOH,−
Cf12 0+1、−CIl20503 H,−CH2
CH(C113) 2、ClI2 5−CI2 CF3
、− (C112) 4 C113、Cl12 S
−Cf12C1l−’C112、−C112−S −C
112−C113、−CH(C113> CIl (
C113) C112C113、(以下余白)
一般′式(3)で示される〔ベンゾ−1,2,4−チア
ジアジン〕−1−ジオキサイド誘導体は、従来から高血
圧治療剤として知られているジアゾキシド(7−クロロ
−3−メチル−2H−1,2,4−ベンゾチアジアジン
−1,1−ジオキサイド;一般式(3)においてR1=
C1,、R2=HSR3=CH3、R4−Hの化合物)
の副作用としての多毛症の発生〔ザ ジャーナル オン
ペディアトリクス(The Journal of
Pediatrics ) 、71、(4)、494〜
505.1967)に基づいて、毛髪育成促進剤として
応用、特許出願されたものである。Alkyl group having 1 to 3 carbon atoms, -C11,2CI, -C
IICI2, -CCI ko, -COOH,-
Cf12 0+1, -CIl20503 H, -CH2
CH(C113) 2, ClI2 5-CI2 CF3
, - (C112) 4 C113, Cl12 S
-Cf12C1l-'C112, -C112-S -C
112-C113, -CH(C113>CIl (
[benzo-1,2,4-thiadiazine]-1-dioxide derivative represented by the general formula (3) is diazoxide (7-dioxide), which has been known as a hypertension treatment agent. Chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide; In general formula (3), R1=
C1,, R2=HSR3=CH3, R4-H compound)
The occurrence of hirsutism as a side effect of
Pediatrics), 71, (4), 494~
505.1967), it was applied as a hair growth promoter and a patent application was filed.
しかしながらその発毛、養毛促進効果は少量使用では非
常に弱く、その効果を得るために大量使用すると過血糖
等の副作用を生じるため、発毛、養毛促進*Fとして使
用するには好ましくないという欠点を有している。However, the effect of promoting hair growth and hair growth is very weak when used in small amounts, and when used in large quantities to obtain the effect, side effects such as hyperglycemia occur, so it is not recommended for use as a hair growth and hair growth promotion*F. It has the following drawbacks.
本発明者らは、このものを上記特定のステロイド誘導体
と併用することによって副作用もなく発毛、養毛効果も
優れた養毛料としたものである。By using this product in combination with the above-mentioned specific steroid derivatives, the present inventors have created a hair nourishing agent that has no side effects and has excellent hair growth and hair nourishing effects.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明社用いられる一般式(1)および一般式(2)の
化合物を具体的に述べると、17β−(2−ヒドロキシ
エトキシ)−4−エストレン−3−オン、17β−(2
−ヒドロキシエトキシ)−4−エストレン−3−オンア
セテート、17β−(2−ヒドロキシエトキシ)−4−
エストレン−3オンブチレート、17β−(2−ヒドロ
キシエトキシ)−4−エストレン−3−オンp−)ルエ
ンスルフォネート、17β−(2−ヒドロキシエトキシ
)−4−エストレン−3−オンメタンスルフォ*−1−
217β−(2−クロロエトキシ)−4−エストレン−
3−オン、17β−(2−ヨードエトキシ)−4−エス
トレン−3−オン、17β−カルボキシメトキシ−4−
エストレン−3−オン、17β−カルボキシメトキシ−
4−エストレン−3−オンメチルエステル、17β−(
2−シアノエトキシ)−4−エストレン−3−オン、1
7β−(2−ピペリジノエトキシ)=4−エストレン−
3−オン、17β−
(2−((テトラヒドロビラン−2−イル)オキシ)エ
トキシ〕 −4−エストレン−3−オン、 17β−(
2−ヒドロキシエトキシ)−4−アンドロステン−3−
オン、17β−(2−ヒドロキシエトキシ)−4−アン
ドロス・テン−3−オンアセテート、17β−(2−ヒ
ドロキシエトキシ)−4−アンドロステン−3−オンブ
チレート、17β−(2−ヒドロキシエトキシ)4−ア
ンドロステン−3−オンP−)ルエンスルフォネート、
17β−(2−ヒドロキシエトキシ)−4−アンドロス
テン−3−オンメタンスルフォネート、17β−(2−
クロロエトキシ)−4−アンドロステン−3−オン、1
7β−(2−ヨードエトキシ)−4−アンドロステン−
3−オン、17β−カルボキシメトキシ−4−アンドロ
ステン−3−オン、17β−カルボキシメトキシ−4−
アンドロステン−3−オン−メチルエステル、17β−
(2−シアノエトキシ)−4−アンドロステン−3−オ
ン、17β−(2−ピペリジノエトキシ)−4−アンド
ロステン−3−オン、17β−(2−((テトラヒドロ
ピラン−2−イル)オキシ)エトキシツー4−アンドロ
ステン=3−オン、4−アンドロステン−3,17−ジ
オノー1フーサイクリンクー1°、2°−プロピレンケ
タール、4−アンドロステン−3,17−シオンー17
−サイクリック−2’、 3’−ブチレンケタール、4
−エストレン−3−オン−17β−カルボン酸メチルエ
ステル、4−アンドロステン−3−オン−17β−カル
ボン酸メチルエステルなどを挙げることができる。Specifically describing the compounds of general formula (1) and general formula (2) used by the present invention, 17β-(2-hydroxyethoxy)-4-estren-3-one, 17β-(2
-hydroxyethoxy)-4-estren-3-one acetate, 17β-(2-hydroxyethoxy)-4-
Estren-3-one butyrate, 17β-(2-hydroxyethoxy)-4-estren-3-one p-)luenesulfonate, 17β-(2-hydroxyethoxy)-4-estren-3-one methanesulfo*- 1-
217β-(2-chloroethoxy)-4-estrene-
3-one, 17β-(2-iodoethoxy)-4-estren-3-one, 17β-carboxymethoxy-4-
Estren-3-one, 17β-carboxymethoxy-
4-estren-3-one methyl ester, 17β-(
2-cyanoethoxy)-4-estren-3-one, 1
7β-(2-piperidinoethoxy)=4-estrene-
3-one, 17β-(2-((tetrahydrobilan-2-yl)oxy)ethoxy)-4-estren-3-one, 17β-(
2-hydroxyethoxy)-4-androstene-3-
17β-(2-hydroxyethoxy)-4-androsten-3-one acetate, 17β-(2-hydroxyethoxy)-4-androsten-3-one butyrate, 17β-(2-hydroxyethoxy)4-one Androsten-3-one P-)luenesulfonate,
17β-(2-hydroxyethoxy)-4-androsten-3-one methanesulfonate, 17β-(2-
chloroethoxy)-4-androsten-3-one, 1
7β-(2-iodoethoxy)-4-androstene-
3-one, 17β-carboxymethoxy-4-androsten-3-one, 17β-carboxymethoxy-4-
Androsten-3-one-methyl ester, 17β-
(2-cyanoethoxy)-4-androsten-3-one, 17β-(2-piperidinoethoxy)-4-androsten-3-one, 17β-(2-((tetrahydropyran-2-yl) oxy)ethoxy2-4-androstene=3-one, 4-androstene-3,17-dione-1 fucyclink-1°,2°-propylene ketal, 4-androstene-3,17-dione-17
-cyclic-2', 3'-butylene ketal, 4
-estren-3-one-17β-carboxylic acid methyl ester, 4-androsten-3-one-17β-carboxylic acid methyl ester, and the like.
その配合量は本発明の養毛料中o、ooot〜2重量%
が望ましい。特に好ましくは、o、ooot〜0.2重
量%である。The blending amount is o,ooot~2% by weight in the hair nourishment of the present invention.
is desirable. Particularly preferred is o,ooot to 0.2% by weight.
o、ooot重量%未満では養毛効果が発揮できない場
合がある。また、配合量が多い程養毛効果は大きいが、
多量に用いられた時の予期せぬ副作用の発現などを考え
ると2重量%以下が好ましい。If the amount is less than o,ooot% by weight, the hair nourishing effect may not be exhibited. In addition, the higher the amount, the greater the hair-nourishing effect.
Considering the occurrence of unexpected side effects when used in large amounts, the amount is preferably 2% by weight or less.
また、下記一般式(3)で示される〔ベンゾ−1゜2.
4−チアジアジン)−1−ジオキサイド誘導体としては
、7−クロロ−3−メチル−2H−1゜2.4−ベンゾ
チアジアジン−1,1−ジオキサイド、7−クロロ−3
−ヒドロキシメチル−2H−1,2,4−ベンゾチアジ
アジン−1,1−ジオキサイド、7−クロロ−3−カル
ボキシル−2H−1,2,4−ベンゾチアジアジン−1
,1−ジオキサイドなどを挙げることができる。Further, [benzo-1゜2.
Examples of the 4-thiadiazine)-1-dioxide derivatives include 7-chloro-3-methyl-2H-1゜2.4-benzothiadiazine-1,1-dioxide, 7-chloro-3
-Hydroxymethyl-2H-1,2,4-benzothiadiazine-1,1-dioxide, 7-chloro-3-carboxyl-2H-1,2,4-benzothiadiazine-1
, 1-dioxide, and the like.
その配合量は本発明の養毛料中0.001〜10重量%
が好ましく、特に好ましくは0.01〜6重量%である
。The blending amount is 0.001 to 10% by weight in the hair nourishment of the present invention.
is preferred, particularly preferably 0.01 to 6% by weight.
0.001 ii量%未満では養毛効果が発揮できない
場合がある。また、配合量が多い程養毛効果は大きいが
、多量に用いられた時の副作用の発現などを考えると1
0重量%以下が好ましい。If the amount is less than 0.001%, the hair nourishing effect may not be exhibited. In addition, the higher the amount, the greater the hair growth effect, but considering the occurrence of side effects when used in large amounts,
It is preferably 0% by weight or less.
本発明に係る養毛料には上記のステロイド誘導体と【ベ
ンゾ−1,2,4−チアジアジンツー1−ジオキサイド
誘導体のほか、通常養毛料に用いられる添加剤、例えば
ヒノキチオール、ヘキサクロロフェン、フェノール、ベ
ンザルコニウムクロリド、セチルピリジニウムクロリド
、ウンデシレン酸、トリクロロカルバニリドおよびビチ
オノールなどの抗菌剤、メントールなどの清涼剤、サリ
チル酸、亜鉛及びその誘導体、乳酸及びそのアルキルエ
ステルなどの薬剤、オリーブ油、スクヮラン、流動パラ
フィン、イソプロピルミリステート、高級脂肪酸、高級
アルコールなどの油分、その他界面活性剤、香料、酸化
防止剤、紫外線吸収剤、色素、エタノール、水、保湿剤
、増粘剤などが本発明の効果を損なわない範囲で適宜配
合することができる。In addition to the above-mentioned steroid derivatives and benzo-1,2,4-thiadiazine-1-dioxide derivatives, the hair care product of the present invention contains additives commonly used in hair care products, such as hinokitiol, hexachlorophene, and phenol. , antibacterial agents such as benzalkonium chloride, cetylpyridinium chloride, undecylenic acid, trichlorocarbanilide and bithionol, cooling agents such as menthol, drugs such as salicylic acid, zinc and its derivatives, lactic acid and its alkyl esters, olive oil, squalane, Oils such as liquid paraffin, isopropyl myristate, higher fatty acids, and higher alcohols, other surfactants, fragrances, antioxidants, ultraviolet absorbers, pigments, ethanol, water, humectants, thickeners, etc. can enhance the effects of the present invention. It can be blended as appropriate within a range that does not cause any damage.
本発明の養毛料の性状は、液状、乳液、軟膏など外皮に
通用できる性状のものであればいずれでもよい。The hair tonic of the present invention may be in any form as long as it can be applied to the outer skin, such as liquid, milky lotion, or ointment.
本発明に係る養毛料は上記のステロイド誘導体と頭皮の
末梢血管を拡張し血流量の増加を促す〔ベンゾ−1,2
,4−チアジアジンツー1−ジオキサイド誘導体とが効
果的に作用し、相乗的な養毛効果を発揮するものである
。The hair tonic according to the present invention contains the above-mentioned steroid derivatives and expands the peripheral blood vessels of the scalp to promote an increase in blood flow [benzo-1,2
, 4-thiadiazine-1-dioxide derivatives to exert a synergistic hair-nourishing effect.
次に実施例をあげて本発明をさらに詳細に説明する。本
発明はこれにより限定されるものではない。配合量は重
量%である。Next, the present invention will be explained in more detail with reference to Examples. The present invention is not limited thereby. The blending amount is in weight%.
実施例に先だち試験法を説明する。Prior to the examples, the test method will be explained.
養毛効果測定法
試料使用前後の洗髪時脱毛本数の変化で判定した。被験
者は実施例1〜6及び比較例1の計7種類の各々の群ご
とに10名とした。測定期間は4力月間とし、前半の2
力月間は試料無塗布の期間、後半の2力月間を試料塗布
の期間とした。この間、2日おきに洗髪して抜毛を回収
し、1週間分をまとめて、その本数を数えた。各期間の
抜毛本数の表示は、試料無塗布の2力月間、計8回の抜
毛本数のデータと養毛剤塗布の2力月間、計8回の抜毛
本数のデータをそれぞれの期間ごとにまとめ、平均値±
αの形で1回当りの抜毛本数として表示した。単位は本
である。効果の判定は、それぞれの期間の平均値の差か
ら次のように表示した。Hair growth effect measurement method Judgment was made based on the change in the number of strands of hair removed during hair washing before and after using the sample. There were 10 subjects in each of seven groups, Examples 1 to 6 and Comparative Example 1. The measurement period is 4 months, and the first two
The first month was the period when no sample was applied, and the second half of the second month was the period when the sample was applied. During this period, the hair was washed every two days and the pulled hair was collected, and the number of hairs for one week was counted. To display the number of hairs pulled out for each period, data on the number of hairs pulled out 8 times in 2 months without sample application and data on the number of hairs pulled out 8 times in 2 months with hair tonic applied are summarized for each period, and the average is calculated. Value ±
The number of hairs pulled per session was expressed in the form of α. The unit is a book. The effectiveness was determined based on the difference between the average values for each period as shown below.
++:抜毛本数が70本以上減っており著しい効果を認
めた。++: The number of hairs pulled was reduced by 70 or more, indicating a significant effect.
+ :抜毛本数が40本以上減っておりかなりの効果を
認めた。+: The number of hairs pulled was reduced by 40 or more, indicating a considerable effect.
± :抜毛本数が10本以上減っておりやや効果ありと
いえた。±: The number of hairs pulled was reduced by 10 or more, and it could be said that there was a slight effect.
−二抜毛木数の減少が10本未満であり効果ありとはい
えない。-The reduction in the number of two-haired trees was less than 10, so it cannot be said that it is effective.
(以下余白) 実施例1、比較例1.2 *EO;ポリオキシエチレンの略、以下同じ。(Margin below) Example 1, Comparative Example 1.2 *EO: Abbreviation for polyoxyethylene, same hereinafter.
(以下余白)
(製造法)
95%エタノールに4−アンドロステン−3−オン−1
7β−カルボン酸メチルエステル、7−クロロ−3−メ
チル−28−1,2,4−ベンゾチアジアジン−1,1
−ジオキサ、イドおよび硬化ヒマシ油EO(40モル)
付加物を添加し、攪拌溶解させ、次いでイオン交換水を
添加、混合して実施例1の透明液状の養毛料を得た。比
較例1.2も実施例1と同様にして得た。(Left below) (Production method) 4-androsten-3-one-1 in 95% ethanol
7β-carboxylic acid methyl ester, 7-chloro-3-methyl-28-1,2,4-benzothiadiazine-1,1
- Dioxa, ido and hydrogenated castor oil EO (40 mol)
The adduct was added, stirred and dissolved, and then ion-exchanged water was added and mixed to obtain a transparent liquid hair nourishment of Example 1. Comparative Example 1.2 was also obtained in the same manner as Example 1.
(以下余白)
(結果)
(以下余白)
前述の結果はすべて、4−アンドロステン−3−オン−
17β−カルボン酸メチルエステルと7−クロロ−3−
メチル−2)i−1,2,4−ベンゾチアジアジン−1
,1−ジオキサイド配合の本発明に係る養毛料が従来公
知の4−アンドロステン−3−オン−17β−カルボン
酸メチルエステル配合の養毛料および7−クロロ−3−
メチル−2H−1,2,4−ベンゾチアジアジン−1,
1−ジオキサイド配合の養毛料に比して、相乗的にその
養毛効果が優れていることを示している。(Below the margins) (Results) (Below the margins) All of the above results are 4-androstene-3-one-
17β-carboxylic acid methyl ester and 7-chloro-3-
Methyl-2)i-1,2,4-benzothiadiazine-1
, 1-dioxide according to the present invention is a hair tonic containing conventionally known 4-androsten-3-one-17β-carboxylic acid methyl ester and 7-chloro-3-
Methyl-2H-1,2,4-benzothiadiazine-1,
This shows that the hair nourishing effect is synergistically superior to that of the hair nourishing agent containing 1-dioxide.
実施例2
(A 相)
4−エストレン−3−オン−
17β−カルボン酸エチルエステル 2.07−ク
ロロ−3−ヒドロキシメチル−
211−1,2,4−ベンゾチアジアジン−■、1−ジ
オキサイド 3.0Eo(60モ
ル)硬化ヒマシ油 2.0グリセリン
7.0ジプロピレングリコール
8.・11丁3−ブチレングリコール
5.0ポリエチレングリコール1500
5.0(B 相)
セチルイソオククネート 10.0スクワ
ラン 5.0ワセリン
2.0プロピルパラベン
2.0(C相)
カルボキシビニルポリマー1%水溶液 30.0へキサ
メタリン酸ソーダ 0.03イオン交換
水 8.95(D 相)
イオン交換水 4.5(E 相
)
カセイカリ 0.12イオ
ン交換水 5.0(l!!造
法)
A相、B相をそれぞれ60℃で加熱溶解し、混合してホ
モミキサー処理しゲルを作る。これにD相を徐々に添加
しホモミキサーで分散する。Example 2 (Phase A) 4-estren-3-one-17β-carboxylic acid ethyl ester 2.07-chloro-3-hydroxymethyl-211-1,2,4-benzothiadiazine-■,1-di Oxide 3.0 Eo (60 mol) Hydrogenated castor oil 2.0 Glycerin
7.0 dipropylene glycol
8.・11-cho 3-butylene glycol
5.0 polyethylene glycol 1500
5.0 (Phase B) Cetyl isooccinate 10.0 Squalane 5.0 Vaseline
2.0 Propylparaben
2.0 (C phase) Carboxyvinyl polymer 1% aqueous solution 30.0 Sodium hexametaphosphate 0.03 Ion exchange water 8.95 (D phase) Ion exchange water 4.5 (E phase) Caustic potash 0.12 Ion exchange water 5.0 (l!! Production method) Phase A and phase B are heated and dissolved at 60°C, mixed and treated with a homomixer to form a gel. Phase D is gradually added to this and dispersed using a homomixer.
次にこ糺に溶解したC相を加え、最後に溶解したE相を
添加しホモミキサーで乳化してO/W乳液型の養毛料を
得た。Next, the dissolved phase C was added to the paste, and finally the dissolved phase E was added and emulsified with a homomixer to obtain an O/W emulsion type hair nourishment.
この養毛料について実施例1と同様に実使用テストを行
ったところ、その養毛効果が優れていることが確認され
た。When this hair nourishing agent was subjected to a practical use test in the same manner as in Example 1, it was confirmed that its hair nourishing effect was excellent.
実施例3
(人 相)
4−アンドロステン−3,17−シオンー17−サイク
リツクニチレンケクール 0.27−クロロ−
3−カルボキシル−
2+1−1.2.4〜ベンゾチアジアジン−■、1−ジ
オキサイド 2.0流動パラフイ
ン 5.0セトステアリルアル
コール 5.1グリセリルモノステアレー
ト 3.0EO(20モル)−2−オクチル
ドデシルエーテル 3.
0プロピルパラベン 0.3香料
0.1(B 相)
グリセリン 8・Oジプロピレ
ングリコール 20.0ポリエチレングリ
コール4000 5.0へキサメタリン酸ソー
ダ o、oosイオン交換水
48.295(製造法)
A相、B相をそれぞれ加熱溶解して混合し、ホモミキサ
ーで乳化して軟膏状養毛料を得た。Example 3 (human face) 4-androstene-3,17-thion-17-cyclic nichilene kecool 0.27-chloro-
3-Carboxyl-2+1-1.2.4~Benzothiadiazine-■,1-dioxide 2.0 Liquid paraffin 5.0 Cetostearyl alcohol 5.1 Glyceryl monostearate 3.0 EO (20 mol) -2 -Octyl dodecyl ether 3.
0 Propyl paraben 0.3 Fragrance 0.1 (B phase) Glycerin 8.O Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 Sodium hexametaphosphate o, oos Ion exchange water
48.295 (Production method) Phase A and phase B were respectively heated and dissolved, mixed, and emulsified with a homomixer to obtain an ointment-like hair nourishing agent.
この養毛料について実施例2と同様に実使用テストを行
ったところ、その養毛効果が優れていることが確認され
た。When this hair nourishing agent was subjected to a practical use test in the same manner as in Example 2, it was confirmed that its hair nourishing effect was excellent.
実施例4
エタノール 55.O17
β−(2−ヒドロキシエトキシ)−4−アンドロステン
−3−オン 0.00017−クロロ−3
−メチル−
211−1,2,4−ベンゾチアジアジン−1,1−ジ
オキサイド 0.01EO(8モ
ル)オレイルアルコール
エーテル 2.0ヒノキ
チオール 0.05香料
0.1染料
0.0899イオン交換水
42.75(製造法)
エタノールにEO(8モル)オレイルアルコールエーテ
ル、17β−(2−ヒドロキシエトキシ)−4−アンド
ロステン−3−オン、7−クロロ−3−メチル−21m
−1,2,4−ベンゾチアジアジン−1,1−ジオキサ
イド、ヒノキチオールを加え、これに香料、染料を加え
て溶解した後、イオン交換水を加えて可溶化し養毛料を
得た。Example 4 Ethanol 55. O17
β-(2-hydroxyethoxy)-4-androsten-3-one 0.00017-chloro-3
-Methyl- 211-1,2,4-benzothiadiazine-1,1-dioxide 0.01 EO (8 mol) Oleyl alcohol ether 2.0 Hinokitiol 0.05 Fragrance
0.1 dye
0.0899 ion exchange water
42.75 (Production method) Ethanol with EO (8 mol) oleyl alcohol ether, 17β-(2-hydroxyethoxy)-4-androsten-3-one, 7-chloro-3-methyl-21m
-1,2,4-benzothiadiazine-1,1-dioxide and hinokitiol were added thereto, perfume and dye were added and dissolved, and then ion-exchanged water was added to solubilize to obtain a hair nourishing agent.
実施例5
17β−(2−ヒドロキシエトキシ)−4−エストレン
−3−オンアセテート0.2g 、 ?−クロロー3−
メチルー211−1.2.4−ベンゾチアジアジン−1
,1−ジオキサイド0.001g 、流動パラフィン5
.0g、セトステアリルアルコール5.5g、ワセリン
5.5g、グリセリルモノステアレート3.0g5EO
(20モル)−2−オクチルドデシルエーテル3.0g
、プロピルパラベン 0゜2gおよび香料0.1gを加
熱熔解、混合する。これにグリセリン7.0g、ジプロ
ピレングリコール20.0g 。Example 5 0.2 g of 17β-(2-hydroxyethoxy)-4-estren-3-one acetate, ? -Kuroro 3-
Methyl-211-1.2.4-benzothiadiazine-1
, 1-dioxide 0.001g, liquid paraffin 5
.. 0g, cetostearyl alcohol 5.5g, petrolatum 5.5g, glyceryl monostearate 3.0g 5EO
(20 mol)-2-octyldodecyl ether 3.0g
, 0.2 g of propylparaben and 0.1 g of fragrance are heated and melted and mixed. Add 7.0g of glycerin and 20.0g of dipropylene glycol to this.
5.0gのポリエチレングリコール4000、ヘキサメ
タリン酸ソーダ0.005gおよびイオン交換水45.
494gの熱溶解混合物を添加し、ホモミキサーにて乳
化してクリーム状養毛料を得た。5.0 g of polyethylene glycol 4000, 0.005 g of sodium hexametaphosphate and 45.0 g of ion exchange water.
494 g of the hot melt mixture was added and emulsified using a homomixer to obtain a cream-like hair nourishing agent.
得られた養毛料は優れた養毛効果を示した。The obtained hair nourishing agent showed an excellent hair nourishing effect.
本発明の養毛料は優れた養毛効果を有し、かつ局所的に
有効で、全身的には副作用がなく、皮膚刺激性の少ない
安全性の高い養毛料である。The hair growth agent of the present invention has an excellent hair growth effect, is locally effective, has no systemic side effects, and is a highly safe hair growth agent with little skin irritation.
特許出願人 株式会社 資 生 堂
手続ネ11正書(自発)
昭和61年4月30
特許庁長官 宇 賀 道 部 殿
1、事件の表示
昭和61年特許願第46771号
2、発明の名称
養毛料
3、補正をする者
事件との関係 特許出願人
明8(111Fの「特許請求の範囲」の欄および「発明
の詳細な説明」の欄
5、補正の内容
(11特許請求の範囲を別紙の通り補正します。Patent applicant: Shiseido Co., Ltd. Procedural Procedures No. 11 (spontaneous) April 30, 1985 Director General of the Patent Office Michibe Uga 1, Indication of the case 1986 Patent Application No. 46771 2, Name of the invention Hair tonic 3. Relationship with the case of the person making the amendments I will correct it accordingly.
(2)明細書第9頁一般式で2)の次に以下の文章を挿
入します。(2) Insert the following sentence after 2) in the general formula on page 9 of the specification.
[(式中R1はHl−C1(3を表わし、R2はHl−
CH3、−C2H5、−c3H7を表わす。)」以上
(別紙)
2、特許請求の範囲
下記(a)の群の中から選ばれる少なくとも一種と、下
記(b)の群の中から選ばれる少なくとも一種とを含有
することを特徴とする養毛料。[(In the formula, R1 represents Hl-C1(3, R2 represents Hl-
Represents CH3, -C2H5, -c3H7. )'' (Attachment) 2. Claims Claims A food product characterized by containing at least one member selected from the group (a) below and at least one member selected from the group (b) below. Hair fee.
(a)■下記一般式illで示される4−エストレン−
3−オン−17β−エトキシ誘導体もしくは4−アンド
ロステン−3−オン−17β−エトキシ誘導体。(a) ■ 4-estrene- represented by the following general formula ill
3-one-17β-ethoxy derivative or 4-androsten-3-one-17β-ethoxy derivative.
(以下余白)
(式中R1は■]、−CIl3を表わし、R2は−CI
l20i+、−CIl20COX (但しXは炭素数1
〜5のアルキル基、フェニル基を表わす。)、−CH2
Y(但しYはF、CI、口r、 Eを表わす。)、−
C112CN、 −C00X (但しXは上記と同一)
、■下記一般式(2)で示される4−アンドロステン−
3,17−シオンー17−サイクリツクニチレンケクー
ル誘導体。(Left below) (In the formula, R1 represents ■], -CIl3, and R2 represents -CI
l20i+, -CIl20COX (X is 1 carbon number
~5 represents an alkyl group or a phenyl group. ), -CH2
Y (however, Y represents F, CI, mouth r, E), -
C112CN, -C00X (X is the same as above)
, ■ 4-androstene represented by the following general formula (2)
3,17-Sion-17-Cyclic Nethylene Kecool Derivative.
R,R2
(以下余白)
■4−アンドロステンー3−オンー17β−カルボン酸
アルキルエステル。R, R2 (blank below) ■4-Androsten-3-one-17β-carboxylic acid alkyl ester.
■4−ニストレンー3−オンー17β−カルボン酸およ
びそのアルキルエステル。(2) 4-Nistrene-3-one-17β-carboxylic acid and its alkyl ester.
■4−ニストレンー3.17−シオンー17−サイクリ
ックエチレンケタノール。■4-Nistrene-3.17-Sion-17-cyclic ethylene ketanol.
(b)下記一般式(3)で示される〔ベンゾ−1,24
−チアジアジン〕−1−ジオキサイド誘導体。(b) [benzo-1,24
-thiadiazine]-1-dioxide derivative.
(式中R8はC1、−CF3、−5o2N112を表わ
し、R2はI(、Ct、−50,2NIl、2を表わし
く但しRIおよびR2が両方同時にCIであることある
。いは両方同時に−502Nl+2であることはない)
、R3は!(、炭素数1〜3 のアルキル基、−CIl
、2 CI。(In the formula, R8 represents C1, -CF3, -5o2N112, and R2 represents I(, Ct, -50,2NIl, 2. However, RI and R2 may both be CI at the same time. Or both may be -502Nl+2 at the same time. )
, R3 is! (, alkyl group having 1 to 3 carbon atoms, -CIl
, 2 CI.
−CIICI2、−CCI 3、−COOII、−C1
12011、−C1120S03 Hl ClI2 C
Il (CIl3 ) 2、ClI2 S Cl1
2 CF3 、(CIl2 ) 4 Cll3、− C
lI2− S −CIl2− CII= C112、C
lI2 S C112C113、C1l (C11
3) CIl (CIl3 ) C112CH3、
以上-CIICI2, -CCI3, -COOII, -C1
12011, -C1120S03 Hl ClI2 C
Il (CIl3) 2, ClI2 S Cl1
2 CF3, (CIl2) 4 Cll3, -C
lI2- S -CIl2- CII= C112, C
lI2 S C112C113, C1l (C11
3) CIl (CIl3) C112CH3,
that's all
Claims (1)
記(b)の群の中から選ばれる少なくとも一種とを含有
することを特徴とする養毛料。 (a)[1]下記一般式(1)で示される4−エストレ
ン−3−オン−17β−エトキシ誘導体もしくは4−ア
ンドロステン−3−オン−17β−エトキシ誘導体。 ▲数式、化学式、表等があります▼(1) {式中R_1はH、−CH_3を表わし、R_2は−C
H_2OH、−CH_2OCOX(但しXは炭素数1〜
5のアルキル基、フェニル基を表わす。)、−CH_2
Y(但しYはF、Cl、Br、Iを表わす。)、−CH
_2CN、−COOX(但しXは上記と同一)、−CH
_2OSO_2C_6H_4CH_3、−CH_2OS
O_2CH_3、▲数式、化学式、表等があります▼、
▲数式、化学式、表等があります▼を表わす。} [2]下記一般式(2)で示される4−アンドロステン
−3、17−ジオン−17−サイクリックエチレンケタ
ール誘導体。 ▲数式、化学式、表等があります▼(2) [3]4−アンドロステン−3−オン−17β−カルボ
ン酸アルキルエステル。 [4]4−エストレン−3−オン−17β−カルボン酸
およびそのアルキルエステル。 [5]4−エストレン−3、17−ジオン−17−サイ
クリックエチレンケタノール。 (b)下記一般式(3)で示される〔ベンゾ−1,2,
4−チアジアジン〕−1−ジオキサイド誘導体。 ▲数式、化学式、表等があります▼(3) (式中R_1はCl、−CF_3、−SO_2NH_2
を表わし、R_2はH、Cl、−SO_2NH_2を表
わし(但しR_1およびR_2が両方同時にClである
ことあるいは両方同時に−SO_2NH_2であること
はない)、R_3はH、炭素数1〜3のアルキル基、−
CH_2Cl、−CHCl_2、−CCl_3、−CO
OH、−CH_2OH、−CH_2OSO_3H、−C
H_2CH(CH_3)_2、−CH_2−S−CH_
2CF_3、−(CH_2)_4CH_3、−CH_2
−S−CH_2−CH=CH_2、−CH_2−S−C
H_2−CH_3、 −CH_(CH_3)CH(CH_3)CH_2CH_
3、▲数式、化学式、表等があります▼、▲数式、化学
式、表等があります▼ ▲数式、化学式、表等があります▼、▲数式、化学式、
表等があります▼、▲数式、化学式、表等があります▼ ▲数式、化学式、表等があります▼、▲数式、化学式、
表等があります▼を表わし、R_4はH、−CH_3を
表わす。)[Scope of Claims] A hair nourishing agent comprising at least one selected from the group (a) below and at least one selected from the group (b) below. (a) [1] A 4-estren-3-one-17β-ethoxy derivative or a 4-androsten-3-one-17β-ethoxy derivative represented by the following general formula (1). ▲There are mathematical formulas, chemical formulas, tables, etc.▼(1) {In the formula, R_1 represents H, -CH_3, and R_2 represents -C
H_2OH, -CH_2OCOX (however, X is a carbon number of 1 to
5 represents an alkyl group or a phenyl group. ), -CH_2
Y (however, Y represents F, Cl, Br, I), -CH
_2CN, -COOX (X is the same as above), -CH
_2OSO_2C_6H_4CH_3, -CH_2OS
O_2CH_3, ▲There are mathematical formulas, chemical formulas, tables, etc.▼,
▲Represents mathematical formulas, chemical formulas, tables, etc.▼. } [2] 4-androstene-3,17-dione-17-cyclic ethylene ketal derivative represented by the following general formula (2). ▲Contains mathematical formulas, chemical formulas, tables, etc.▼(2) [3] 4-Androsten-3-one-17β-carboxylic acid alkyl ester. [4] 4-estren-3-one-17β-carboxylic acid and its alkyl ester. [5] 4-estrene-3,17-dione-17-cyclic ethylene ketanol. (b) [benzo-1,2,
4-thiadiazine]-1-dioxide derivative. ▲There are mathematical formulas, chemical formulas, tables, etc.▼(3) (In the formula, R_1 is Cl, -CF_3, -SO_2NH_2
, R_2 represents H, Cl, -SO_2NH_2 (however, R_1 and R_2 are not both Cl or -SO_2NH_2 at the same time), R_3 is H, an alkyl group having 1 to 3 carbon atoms, −
CH_2Cl, -CHCl_2, -CCl_3, -CO
OH, -CH_2OH, -CH_2OSO_3H, -C
H_2CH(CH_3)_2, -CH_2-S-CH_
2CF_3, -(CH_2)_4CH_3, -CH_2
-S-CH_2-CH=CH_2, -CH_2-S-C
H_2-CH_3, -CH_(CH_3)CH(CH_3)CH_2CH_
3. ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼, ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼, ▲ Mathematical formulas, chemical formulas,
There are tables, etc. ▼, ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼, ▲ Mathematical formulas, chemical formulas,
It represents ▼, and R_4 represents H, -CH_3. )
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4677186A JPS62205010A (en) | 1986-03-04 | 1986-03-04 | Hair tonic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4677186A JPS62205010A (en) | 1986-03-04 | 1986-03-04 | Hair tonic |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62205010A true JPS62205010A (en) | 1987-09-09 |
Family
ID=12756590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4677186A Pending JPS62205010A (en) | 1986-03-04 | 1986-03-04 | Hair tonic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62205010A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003086348A1 (en) * | 2002-04-08 | 2003-10-23 | Dermcare-Vet Pty Ltd | Allergic dermatitis formulation and method of treatment |
US9861645B2 (en) | 2012-12-28 | 2018-01-09 | Rak Holdings Llc | Anti-itch scalp treatment compositions and combinations |
-
1986
- 1986-03-04 JP JP4677186A patent/JPS62205010A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003086348A1 (en) * | 2002-04-08 | 2003-10-23 | Dermcare-Vet Pty Ltd | Allergic dermatitis formulation and method of treatment |
US9861645B2 (en) | 2012-12-28 | 2018-01-09 | Rak Holdings Llc | Anti-itch scalp treatment compositions and combinations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6293215A (en) | Hair tonic | |
JPS6127914A (en) | Cosmetic | |
JPS62205010A (en) | Hair tonic | |
JP3480954B2 (en) | External preparation for skin | |
JP3105345B2 (en) | Cosmetics | |
JP2696523B2 (en) | Anti-dandruff agent and hair cosmetic | |
JPS61171413A (en) | Hair tonic | |
JP2566792B2 (en) | Hair growth and hair growth promoter | |
JP2879596B2 (en) | Hair cosmetics | |
JPS63267711A (en) | Cosmetic | |
JPS6284016A (en) | Hair tonic | |
JP2862623B2 (en) | Hair restoration | |
JPS6284012A (en) | Hair tonic | |
JPH0481563B2 (en) | ||
JPH07149614A (en) | Hair tonic agent | |
JPS6284013A (en) | Hair tonic | |
JPS62132810A (en) | Cosmetic | |
JPS6054310A (en) | Cosmetic | |
JPS6284015A (en) | Hair tonic | |
JPS6293214A (en) | Hair tonic | |
JPH0669955B2 (en) | External preparation for sebum control | |
JPS59172412A (en) | Hair tonic | |
JPH0667819B2 (en) | Hair cosmetics | |
JPH0577647B2 (en) | ||
JPS6284011A (en) | Hair tonic |